News:

Here we provide you with news articles, blogs and tweets on the key aspects of our genomics, epigenomics, bioinformatics and training work.

In this new section of the krisp.org.za website, we disseminate printed and online media coverage of our work and its application in everyday life.


News Latest News

EurekaAlert!


CD4+ T-cell count useful to assess antiretroviral therapy response in HTLV-1/HIV patients?

EurekaAlert! - 2017-03-17

News coverage and clinical management implication of our recent HIV/HTLV co-infection manuscript, Current HIV Research, 2017


Click on the CD4 image to access our publication

The authors compared the CD4+ T-cell counts and HIV-1 RNA viral loads of 383 patients who were either mono-infected with HIV or co-infected with HTLV-1/HIV. They confirmed that co-infected patients were more likely to have higher CD4+ T-cell counts prior to treatment initiation with no immunologic benefit--a result that has been well documented in scholarly literature. Any differences in the CD4+ T-cell counts were expected to disappear once the co-infected and mono-infected patients began to fail their antiretroviral therapy (ART) regimens.

Instead, the authors found that HTLV-1/HIVco-infected patients continued to have elevated CD4+ T-cell counts, on average 115 cells/uL higher than their HIV mono-infected counterparts, over the two-year study period. But when the authors compared the HIV viral loads over the same period, they could not find any statistically significant difference between the two groups of patients.

HIV viral load testing is currently recommended by the World Health Organization (WHO) as an accurate strategy for monitoring a patient's response to ART. Nevertheless, CD4+ T-cell testing is often used in resource-limited settings because it is perceived to be more affordable. The continued use of CD4+ T-cell testing has implications for the clinical management of HIV-positive patients. Results from the present study suggest that HTLV-1/HIV co-infection could delay the identification of patients who are failing ART with adverse consequences.

Against this background, recent scientific research has begun to show that HIV viral load testing can be both an accurate and cost-effective treatment monitoring strategy. The present study was based in the KwaZulu-Natal province of South Africa and used patient data from a poor and rural community at the epicentre of the global HIV epidemic.

This article by Dr. Alain Vandormael et al has been published in Current HIV Research, Volume 15, 2017

Links:

https://www.eurekalert.org/pub_releases/2017-03/bsp-ctc031717.php

Publication cited

CD4+ T-cell count may not be a useful strategy to monitor antiretroviral therapy response in HTLV-1/HIV co-infected patients. Vandormael A, Rego F, Danaviah S, Alcantara L, Boulware D, de Oliveira T, Current HIV Research (2017), :doi: 10.2174/1570162X15666170216114917.

15 minutes, All news...

A multi-centre analysis of internal migration and AIDS/TB and NCD-related mortality in Kenya and South Africa
From KRISP Talks, date: 2017-08-23

KRISP & SANTHE trainee wins Best Abstract at DELTAS Africa meeting
From KRISP News, date: 2017-07-19

Durban at the forefront of DNA research - KwaZulu-Natal Research and Innovation Sequencing Platform - KRISP
From KRISP News, date: 2017-07-15
15 minutes, All news...


KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN

Contact: Prof. Tulio de Oliveira, Tel: +27 31 260 4898, Email: tuliodna@gmail.com & deoliveira@ukzn.ac.za

Page design updated 2015. Many of the pages were previously hosted at bioafrica.net.